PT-141 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PT-141 is FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. Regulations vary by country, and the legal landscape for peptides is evolving. This guide covers the current legal status and what researchers need to know.
Is PT-141 Legal?
FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers.
The legal landscape for peptides like PT-141 is nuanced and varies by jurisdiction. This guide covers the current regulatory status and what researchers need to know.
What Is the Legal Status of PT-141 in the United States?
PT-141 is generally available as a research chemical in the US. It is not FDA-approved for human use, which means it cannot be marketed, sold, or prescribed as a drug or supplement.
However, research chemicals can be legally purchased for laboratory, in vitro, or educational use. The key legal distinction is between personal research use and human consumption — the latter is not approved.
Is PT-141 Legal Internationally?
Peptide regulations vary significantly by country. Some jurisdictions classify peptides as prescription-only compounds, while others allow research chemical sales similar to the US.
Australia: Most peptides require a prescription. UK: Generally available for research. Canada: Research chemical status. EU: Varies by country. Always check local regulations before purchasing.
Is PT-141 Banned in Sports?
PT-141 may be subject to anti-doping regulations depending on its class and mechanism. Athletes should check the current WADA prohibited list.
If you compete in any organized sport, assume all peptides are prohibited unless you have confirmed otherwise with your sport's governing body.
How Is the Legal Landscape Changing?
Peptide regulation is an evolving area. The FDA has increased scrutiny of compounding pharmacies and research chemical vendors in recent years. Some peptides that were freely available have faced new restrictions.
Staying informed about regulatory changes is important for researchers working with PT-141 and similar compounds.
Bottom Line on PT-141 Legality
FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. Researchers should ensure compliance with their local laws and use PT-141 only for legitimate research purposes.
Complete Guide
PT-141 (Bremelanotide): Research
Related Reading
- PT-141 Dosage Guide
- PT-141 Benefits
- PT-141 Side Effects
- PT-141 Stacking Guide
- PT-141 Cycle Guide
- PT-141 Research
Calculate Your PT-141 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PT-141.
Open Calculator →Research-Grade Sourcing
If you're going to research PT-141, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages: 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycle length: on-demand acute dosing; no continuous cycle required. Half-life: peak effects 15-30 minutes post-injection. Use our peptide calculator for exact reconstitution math.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 safe?
PT-141 has shown a preliminary safety profile in research. FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. All research should follow appropriate safety protocols.